6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Genetic Disorder: new trials by email Literature Review of Genetic Disorder trials Research Report on Genetic Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome somatropin - Genetic Disorder, Noonan Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 51 | 2013-08-19 | 2020-08-10 |
| Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 somatropin - Genetic Disorder, Noonan Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 22 | 2008-09-01 | 2023-08-09 |
| Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 3 | Completed | Novo Nordisk A/S | 168 | 2000-10-23 | 2017-02-27 |
| Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome 17-beta estradiol - Genetic Disorder, Turner Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 50 | 1998-07-23 | 2017-02-28 |
| Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome somatropin - Genetic Disorder, Noonan Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 24 | 1990-06-01 | 2017-01-18 |
| Use of Somatropin in Turner Syndrome somatropin - Genetic Disorder, Turner Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 57 | 1987-09-14 | 2017-02-28 |
Genetic Diseases, Inborn (6) · Noonan Syndrome (3) · Turner Syndrome (3)
Cardiovascular Abnormalities (6) · Cardiovascular Diseases (6) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Heart Defects, Congenital (6) · Heart Diseases (6) · Chromosome Disorders (3) · Connective Tissue Diseases (3) · Craniofacial Abnormalities (3) · Disorders of Sex Development (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gonadal Disorders (3) · Gonadal Dysgenesis (3)
Human Growth Hormone (5) · Estradiol (1)
Novo Nordisk A/S (6)
Sweden (2) · Israel (1) · Japan (1) · Spain (1) · United Kingdom (1)
PMID 16203673, PMID 29109363, PMID 32269181, PMID 41285480
2005 (1), 2008 (1)